89 results
Page 4 of 5
6-K
EX-99.1
5gpf24nt 9jb025u0qtd
21 Oct 19
Current report (foreign)
5:16pm
6-K
EX-99.1
0ixevffx6o49
30 Sep 19
Current report (foreign)
12:00am
6-K
EX-99.1
9x0efnto9ql867
27 Sep 19
Current report (foreign)
6:05am
6-K
EX-99.1
zpjqahc9ez4 vck
9 Sep 19
Current report (foreign)
6:05am
6-K
EX-99.2
01bz9rrjzf3jt0
3 Sep 19
Current report (foreign)
8:20am
6-K
EX-99.1
tj8mnh5
3 Sep 19
Current report (foreign)
8:20am
6-K
EX-99.1
09ekc6 qvszgv
30 Jul 19
Current report (foreign)
9:48am
6-K
EX-99.1
xfb ie34t1oz
24 Jun 19
GENFIT and Terns Pharmaceuticals Announce $228MM Strategic Partnership to Develop and Commercialize Elafibranor in Greater China
5:20pm
6-K
EX-99.1
0c1jgmo0c
13 Jun 19
Current report (foreign)
5:21pm
6-K
EX-99.1
nr624lq 6i
5 Jun 19
GENFIT Launches a Phase 2 Trial Evaluating Elafibranor on Hepatic Lipid Composition for NAFL
7:40am
6-K
EX-99.1
w3m11p
23 May 19
GENFIT Launches a Combination Therapy Clinical Program in NASH
5:13pm
6-K
EX-99.1
k6eit rknbpil
14 May 19
Shareholders' and Unitholders' Meetings
9:29am
6-K
EX-99.3
pd17w
14 May 19
Shareholders' and Unitholders' Meetings
9:29am
6-K
EX-99.1
tn187
30 Apr 19
Current report (foreign)
8:01am
6-K
EX-99.1
svt50iez
18 Apr 19
GENFIT Announces FDA Grant of Breakthrough Therapy Designation to Elafibranor for the Treatment of PBC
6:04am
6-K
EX-99.1
1npjz
15 Apr 19
GENFIT to Present Additional Data from the Positive Phase 2
8:01am
6-K
EX-99.1
lc72ijrhkwcamdckjy9i
29 Mar 19
GENFIT Announces Closing of Global Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
1:21pm
424B4
pxr pepgv
27 Mar 19
Prospectus supplement with pricing info
4:12pm
F-1/A
EX-4.1
aj5lrd9eg
14 Mar 19
Registration statement (foreign) (amended)
12:54pm
F-1/A
EX-1.1
isad 5j6b
14 Mar 19
Registration statement (foreign) (amended)
12:54pm